Utilizarea medicamentelor biologice pentru bolile autoimune în timpul sarcinii şi lactaţiei

Autoimmune diseases affect mainly women at their reproductive age, putting their mark on fertility, pregnancy outcome and conception product quality. The last year’s advances in therapies have encouraged pregnancies. The new developed immunosuppressive molecules have resulted in a better control of the underlying pathology, but there are still possible adverse effects that should be taken into consideration like: abortion, fetal malformations, intrauterine growth restriction, premature birth, and long-term effects. Biological drugs are IgG-like immunoglobulin molecules that cross the placenta and have a prolonged half-life time into the fetus. The current literature data conclude that the biological therapy is relatively safe when the medication is chosen according to the half-life time, depending on the placental passage and the possible adverse reactions on the fetus and the newborn, but no biological agents can be assumed to be safe since a lack of association is hard to prove.